GeneQuantum Healthcare | May 16, 2022
GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property rights.
"The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates. GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world."
Dr. Gang Qin, founder, Chairman and Chief Executive Officer
About GeneQuantum Healthcare Co., Ltd.
GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally.
This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.
Netsmart | April 12, 2022
Netsmart announced a partnership with Bamboo Health, a leading provider of data and healthcare IT solutions, to create a comprehensive behavioral health referral network supporting the nationwide effort to respond to the need to implement a 988 crisis management system. Through this strategic technology partnership, Netsmart and Bamboo Health will partner to create one of the most robust crisis management solutions in the market. The integrated solution will expedite access to treatment for those in crisis, connect individuals to a network of care and enable effective post-crisis care coordination.
Netsmart will integrate the Bamboo Health OpenBeds solution within the CareManager™ population health management platform, currently utilized by many health home organizations, managed care organizations, human services and post-acute care providers across the country. By working together to connect healthcare providers, emergency departments and crisis response professionals across a national network, OpenBeds and Netsmart will deliver an advanced system to help states, counties and providers respond to 988 and crisis line demands. Streamlining mobile crisis service coordination, treatment facility bed availability, electronic transfers and referrals to behavioral health services, the solution will create a full-picture view of an individual’s journey, including health history and treatment and services, making it easier for providers to get patients engaged with the right level of care they need quickly.
Netsmart and Bamboo Health are excited to announce that the Missouri Behavioral Health Council will be deploying the solution as part of a statewide approach to create a comprehensive statewide crisis network (known as Missouri Behavioral Health Connect – MOConnect). MOConnect will support crisis management for the Missouri Department of Mental Health, Missouri Behavioral Health Council (MBHC) and its member organizations, and community response and health partners across the state. With the vision of MBHC and its members, Missouri Behavioral Health Connect will validate the value of an integrated and connected statewide approach to crisis management and care coordination.
“By collaborating with Netsmart, together we will be able to strengthen our statewide networks to effectively manage and respond to crisis by integrating our OpenBeds solution within the CareManager population health and care coordination platform,” said Bamboo Health CEO Rob Cohen. “Through this innovative technology initiative, we can leverage one of the largest community-based interoperability networks in the country to connect with the larger healthcare ecosystem. Together, we enable care coordination and leverage robust data and analytics for population health management that improves patient outcomes during and post-crisis.”
MBHC, a longtime partner of Netsmart, leverages many components of the CareFabric platform and began using CareManager to eliminate data silos and streamline the complex process of operationalizing population health management in 2016. MBHC members have significantly advanced their workflows using CareManager and have expanded their use cases within the platform to additional programs, including the CCBHC model which is transforming service delivery for Community Mental Health Centers across the country.
“We are excited to be a part of this unique partnership and continue to leverage technology to enable our award-winning care teams across the state with the right technology to support delivering the best care. In Missouri, we are going ‘Beyond the Call’ in our approach to implementing the 988 Crisis Hotline by working together with all stakeholders to ensure individuals in need have not just someone to call in their time of need but connecting them to resources to enable better long term outcomes. By approaching the rollout of a comprehensive crisis system in the context of all of the behavioral health initiatives underway in Missouri, including the CCBHC model, we can make this happen.”
MBHC CEO & President Brent McGinty
The CCBHC model enables agencies to deliver a comprehensive range of physical, mental health and substance use treatment and services, providing expanded care while helping lower costs across the behavioral health ecosystem. Behavioral health providers that achieve CCBHC certification are uniquely positioned to serve as a foundation for the nation’s new crisis response system and Missouri has led the way in proving the value of the CCBHC initiative.
“We are thrilled to announce our new partnership with Bamboo Health, as we collectively redefine how states facilitate crisis management,” said Netsmart CEO Mike Valentine. “We believe teaming up with industry-leading technology providers to further extend the value of our CareFabric platform demonstrates our commitment to innovation and collaboration to meet our clients’ needs. As a longtime partner of MBHC and advocate for CCBHC funding, we couldn’t be happier to see this project come to life and continue to enhance this and other statewide efforts.”
To hear more about the Netsmart, Bamboo Health and MBHC strategic technology partnership stop by the Netsmart booth 313 at the National Council of Mental Wellbeing Conference (NATCON22) in Washington, D.C., April 11 – 13.
About Bamboo Health
Bamboo Health is a healthcare technology solutions company, focused on fostering care collaboration and providing information and actionable insights across the entire continuum of care. As one of the largest, most diverse care collaboration networks in the country, our technology solutions equip healthcare providers and payers with software, information, and insights to facilitate whole person care across the physical and behavioral health spectrums. By serving 2,500 hospitals, 8,000 post-acute facilities, 25,000 pharmacies, 32 health plans, 50 state governments, and over one million acute and ambulatory providers through more than 500 clinical information systems electronically, we impact over 1 billion patient encounters annually in provider workflow. Health systems, payers, providers, pharmacies, governments, individuals, and other organizations rely on Bamboo Health to improve care and reduce cost. Connect with Bamboo Health on Twitter, LinkedIn and Facebook. Visit www.BambooHealth.com to learn more.
About Missouri Behavioral Health Council
The Missouri Behavioral Health Council’s mission is to enable access to quality mental health services to all Missouri citizens in need of such services, while maximizing their human potential and quality of life. This mission will be accomplished through the continued maintenance and development of a stable statewide network of comprehensive community based behavioral healthcare.
Netsmart, a leading provider of Software as a Service (SaaS) technology and services solutions, designs, builds and delivers electronic health records (EHRs), health information exchanges, analytics and telehealth solutions and services that are powerful, intuitive and easy-to-use. Our platform provides accurate, up-to-date information that is easily accessible to care team members in the human services and post-acute care (which is comprised of home care and hospice and senior living) markets. We make the complex simple and personalized so our clients can concentrate on what they do best: provide services and treatment that support whole-person care.
FUTURE OF HEALTHCARE
Spinafx medical inc | June 13, 2022
Minimally invasive image-guided therapy company, SpinaFX Medical Inc. announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting inBoston, MA,June 11-16, at booth 414. Dr. Alexis Kelekis, medical advisor to SpinaFX, will present the results of a research study on which he was the lead author, recently published inThe Spine Journal, on the effectiveness of intradiscal oxygen-ozone treatment compared to microdiscectomy for contained lumbar disc herniation with radiculopathy. This study has been recognized by SIR as one of the 2022Abstracts of the Year.
"We are excited to meet with some of the world's leading interventional radiologists to discuss innovations in minimally invasive, image-guided care and share our recent progress and momentum at SpinaFX. We look forward to Dr. Kelekis' presentation and celebrate the study's findings, which have the potential to benefit both patients and providers by addressing a significant gap in the continuum of care for the millions suffering from back pain."
Jeff Cambra, SpinaFX CEO
"I am thrilled that Dr. Kelekis will share the findings of our skilled research team at SIR's Annual Scientific Meeting," said Dr.Kieran Murphy, SpinaFX Chief Medical Officer and co-author of the recognized study. "The technology used in this randomized control trial holds great promise for patients struggling with contained herniated lumbar disc pain and it is an honor to have this research recognized by such a prestigious and well-respected organization."
Dr. Alexis Kelekis willpresentthe results of his study onWednesday, June 15, at10:40 a.m.during Closing Plenary.
As an exhibitor during the meeting onJune 11-16, SpinaFX will offer attendees the opportunity to discuss the study results and their implications with Drs. Kelekis and Murphy, learn more about SpinaFX and its goal to help develop minimally invasive, image-guided treatment options, and provide input on developing technology with the potential to redefine the treatment of contained herniated discs. Visit SIR'swebsiteto learn more about the Annual Scientific Meeting.
Headquartered inOntario, Canada, SpinaFX is a treatment solution and technology company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to contained herniated discs.
FUTURE OF HEALTHCARE
Dalrada Corporation | June 09, 2022
Dalrada Corporation announced that it had acquired the pharmacy, Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive growth plans within the healthcare sector and paves the way for a total end-to-end total healthcare solution.
Adding the 10-year-old pharmacy to Dalrada Health’s comprehensive model expands the subsidiary’s synergies with potential opportunities across its products and services portfolio and offers another solution to meet patient requirements.
Dalrada envisions a comprehensive healthcare solution for all Dalrada Health clients with unique offerings that will now include: a pharmacy to facilitate prescription processing, physicians and clinicians at treatment clinics, expanding into telemedicine, engagement of Dalrada-owned testing facilities and laboratories, and utilization of Company-specific technologies to facilitate immediate growth of the business.
“Watson Rx has a long history of providing excellent pharmacy services. This acquisition allows Dalrada to expand its healthcare footprint and continue to build a total health management solution on an already successful turnkey operation. As a result, the Company will be able to successfully address the health needs of even more patients.”
CEO and Founder, Brian Bonar
Through comprehensive prescription management, education, nursing, and total health management, Watson Rx Solutions' leadership team holds more than six decades of combined experience in various complex pharmacy disease states and retail services, always putting patients first.
Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage the Company’s existing capabilities. Research reveals that the U.S. online and mail-order sales of drugs, health, and beauty aids were valued at 75.5 billion USD in 2020. Additionally,
E-commerce pharmaceutical sales and beauty aids increased from 51.7 billion USD the year prior.
Online, E-commerce, and mail-order sales increased from around 31 to 38 percent during the same period.
Pharmacy and drug store sales reached 300 billion USD in 2020, with over-the-counter (OTC) medication accounting for over 36 billion USD in sales during the same year, the highest-selling year to date for the OTC segment.
Dalrada and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets.
Dalrada Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible.
The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.